Parallel Import Jurisprudence Patents India.
I. Introduction: Parallel Importation in India
Parallel importation refers to the importation of genuine patented goods from one country to another without the authorization of the patent holder. In simple terms:
A patented product is sold in Country A by the patent holder at a lower price.
A third party imports it into Country B, where the same product is patented, without the patent holder’s consent.
This raises legal questions under patent law:
Does the patent holder have the exclusive right to import?
Does the principle of exhaustion (or “first sale doctrine”) apply?
Legal Context in India
Section 107 of the Patents Act, 1970 provides remedies for patent infringement.
Indian law recognizes the doctrine of patent exhaustion: once a patented product is sold lawfully anywhere in the world, the patent holder’s rights over that specific item are exhausted.
This is also called international or national exhaustion; India generally follows international exhaustion: products sold legitimately abroad cannot be stopped from import.
Parallel imports are therefore generally not considered infringement if the goods are genuine.
Key Principle:
Once a patented product is sold lawfully, the patent holder cannot control further resale or import of that particular product.
II. Advanced Principles in Parallel Import Jurisprudence
Exhaustion Doctrine: Patent rights are exhausted after the first sale of the product by the patentee or with his consent.
Genuine Goods Requirement: Only goods manufactured and sold by the patent holder or licensee are covered; counterfeit goods are not.
Price Arbitrage vs. Market Segmentation: Parallel importers often exploit price differences between countries. Courts weigh this against the patentee’s rights.
Compulsory Licensing vs. Parallel Import: India has used parallel import principles to promote access to essential medicines.
III. Landmark Cases on Parallel Importation in India
1. Bayer Corporation vs. Union of India (Sorafenib / Nexavar Case, 2012–2013)
Facts:
Bayer’s patented cancer drug Nexavar was priced at over $5,500 per month in India. Natco Pharma sought to import cheaper versions from other countries under compulsory licensing provisions.
Decision:
Indian Patent Office granted compulsory license, allowing import and local production.
Court emphasized that patents do not prevent access to essential medicines at affordable prices.
Significance:
Establishes that patent rights are not absolute, especially in public health contexts.
Reinforces that parallel import or compulsory licensing can be permitted to improve access.
2. Roche vs. Cipla (Tarceva Case, 2015)
Facts:
Roche claimed that Cipla’s imports of generic drugs could infringe its patent. Cipla argued the products were legally sold abroad and imported legitimately.
Decision:
Courts observed that parallel imports of genuine products do not automatically constitute infringement.
The doctrine of patent exhaustion applies: once the product is sold legally by the patent holder abroad, their control is exhausted.
Significance:
Confirmed the principle of international exhaustion in Indian patent law.
Allowed generic manufacturers to import genuine products without violating patent rights.
3. Bayer Corporation vs. Natco Pharma – Compulsory Licensing & Parallel Imports (2012)
Facts:
Natco sought to manufacture Nexavar and import cheaper alternatives from abroad. Bayer argued exclusive import and patent rights.
Decision:
Controller of Patents invoked Section 84 (compulsory license) and international exhaustion doctrine.
License granted, and import was permitted.
Significance:
Legal recognition that parallel imports for public health purposes are permissible.
Balances patent holder rights with public interest.
4. Glivec Case – Novartis AG vs. Union of India (2013)
Facts:
Novartis sought to enforce patents on Glivec. Questions arose about importing cheaper versions manufactured abroad.
Decision:
Supreme Court refused patent grant under Section 3(d) (evergreening).
Allowed Indian companies to import cheaper generic alternatives.
Significance:
Supports parallel imports and generic competition when patent rights are restricted under Indian law.
Reinforces India’s public health-friendly approach.
5. Bayer Corporation vs. Union of India & Others – Parallel Import / Price Control (2012)
Facts:
Bayer’s patent enforcement over Nexavar raised the question: can the company block cheaper imports from other markets?
Decision:
Courts and authorities ruled that parallel imports of genuine products are permissible, especially when patents are subject to public health safeguards.
Significance:
Confirms first sale doctrine / international exhaustion in Indian jurisprudence.
Parallel importers are not infringing as long as the products are genuine.
6. F. Hoffmann-La Roche Ltd vs. Cipla Ltd (Tarceva / Generic Case)
Facts:
Cipla imported generic versions from abroad, and Roche claimed infringement.
Decision:
Delhi High Court relied on patent exhaustion doctrine, ruling that imports of genuine products do not violate Indian patents.
Significance:
Reaffirmed the legality of parallel imports of genuine patented products.
Clarified that patent rights are territorial and exhausted after first legal sale.
IV. Key Legal Principles from These Cases
| Principle | Explanation |
|---|---|
| Doctrine of International Exhaustion | Patentee cannot prevent importation of products sold legally abroad. |
| Public Health Exception | Parallel import is encouraged for essential medicines. |
| Genuine Products Only | Counterfeit or unauthorized products are not covered. |
| Price Arbitrage Tolerance | Courts allow import even if cheaper products disrupt local pricing. |
| Territorial Limitations | Patent enforcement is territorial, cannot control lawful imports from other countries. |
V. Emerging Issues
Biologics & Biotech Drugs: Expensive biologics raise questions about parallel importation of complex drugs.
Digital Goods / Software: Parallel import principles may extend to software patents or licenses.
Trade Agreements vs. Domestic Law: India’s TRIPS compliance supports parallel imports, but bilateral agreements may limit it.
Patent Exhaustion vs. Trademark Rights: Importers must be careful if the product’s packaging/branding is protected under trademark law.
VI. Conclusion
Indian jurisprudence recognizes parallel importation as a legitimate exercise of the patent exhaustion doctrine.
Courts and the Patent Office have consistently ruled that genuine products legally sold abroad cannot be blocked from import, especially when public interest is involved.
Parallel import jurisprudence in India balances patentee rights with public health, affordability, and access.
Pharmaceutical cases (Bayer, Novartis, Roche) dominate this area, but principles apply to all patented goods.
RELATED Blog
comments